mug137 Antibody

What is the CD137 (4-1BB) receptor and why is it significant in immunotherapy?

CD137, also known as 4-1BB, is a costimulatory receptor expressed on activated T cells and some activated NK cells. It functions as an important regulatory molecule in the immune response against malignancies. When engaged by agonistic monoclonal antibodies, CD137 enhances immune cell activation, proliferation, and survival, making it a valuable target for cancer immunotherapy approaches. CD137 signaling is particularly important for CD8+ T lymphocyte responses, including strengthening cytotoxic function and promoting memory formation against tumor antigens .

Research indicates that CD137 engagement helps overcome immune suppression in the tumor microenvironment, enabling more effective anti-tumor immunity. Unlike direct tumor-targeting approaches, anti-CD137 therapy works indirectly by stimulating the host immune system rather than attacking cancer cells directly, as evidenced by experiments showing that the plasmacytomas used in preclinical models do not express CD137 on their cell surface .

How does anti-CD137 antibody differ from other immunostimulatory antibodies?

Anti-CD137 antibodies belong to a class of immunostimulatory monoclonal antibodies that include anti-CTLA-4, anti-CD40, and others that enhance immune responses against malignancies. While they share the common goal of boosting anti-tumor immunity, they target different pathways in immune regulation . Anti-CTLA-4 works by blocking inhibitory signals, whereas anti-CD137 delivers activating signals to immune cells.

What immune cell types are involved in anti-CD137 antibody-mediated tumor rejection?

Anti-CD137 antibody therapy engages multiple immune cell populations to orchestrate effective anti-tumor responses. Research has established that both NK cells and CD8+ T lymphocytes are critically required for anti-CD137-mediated tumor rejection. Depletion studies demonstrate that eliminating either cell population abolishes the therapeutic efficacy of anti-CD137 treatment .

Mechanistically, anti-CD137 treatment causes significant increases in both relative and absolute numbers of NK cells (CD3−DX5+ cells) in tumor-draining lymph nodes (TDLNs). While the activation marker CD69 shows similar expression levels on NK cells regardless of treatment, anti-CD137 notably enhances the capacity of NK cells to produce IFN-γ, as determined by intracellular cytokine staining . These effects on NK cell biology in the draining lymph nodes appear crucial for the therapeutic outcome, highlighting the importance of regional immune activation in controlling systemic disease.

What is the role of IFN-γ in anti-CD137 antibody therapy?

IFN-γ serves as an essential mediator in anti-CD137 antibody-mediated tumor rejection. Experiments using both IFN-γ-deficient mice and neutralizing anti-IFN-γ antibodies conclusively demonstrate that normal IFN-γ function is an absolute requirement for tumor rejection following anti-CD137 therapy .

In wild-type BALB/c mice, tumors regressed after anti-CD137 treatment, whereas all IFN-γ-deficient mice developed progressively growing tumors despite receiving identical therapy. Similarly, tumor regression was significantly impaired in mice receiving neutralizing anti-IFN-γ antibodies . The incomplete blockade observed with neutralizing antibodies compared to genetic knockout likely reflects incomplete neutralization rather than IFN-γ-independent mechanisms. These findings point to critical immunomodulatory functions of IFN-γ, potentially including enhanced antigen presentation, promotion of Th1 immune responses, and direct anti-proliferative effects on tumor cells.

What are the optimal dosing schedules for anti-CD137 antibody in preclinical myeloma models?

In preclinical multiple myeloma models, effective dosing schedules for anti-CD137 antibody therapy typically involve intermittent administration to balance efficacy and safety. Research protocols that demonstrated significant anti-tumor activity utilized 100μg doses administered on days 4, 8, 14, and 18 post-tumor cell inoculation . This schedule produces substantial therapeutic effects while avoiding potential toxicities associated with continuous receptor stimulation.

How can researchers assess the efficacy of anti-CD137 antibody therapy in disseminated myeloma models?

Evaluating anti-CD137 antibody efficacy in disseminated myeloma models requires a multi-parameter assessment approach that captures both local and systemic disease burden. Effective protocols incorporate the following methodologies:

What experimental methods are appropriate for investigating the cellular mechanisms of anti-CD137 antibody therapy?

Investigating the cellular mechanisms underlying anti-CD137 antibody therapy requires sophisticated immunological techniques that can track immune cell activation, migration, and function. Researchers should consider implementing the following methodological approaches:

• Flow cytometry phenotyping: Comprehensive immunophenotyping of tumor-infiltrating lymphocytes and cells from secondary lymphoid organs should analyze key markers including CD3, CD4, CD8, CD49b (for NK cells), and activation markers such as CD69. Pre-treatment with Fc-Block (anti-CD16/32) reduces non-specific staining and improves data quality .

• Intracellular cytokine staining: To assess functional activation, lymphocytes from tumor-draining lymph nodes should be stimulated with PMA (5ng/ml) and ionomycin (500ng/ml) for 5 hours, with Brefeldin-A (10μg/ml) and monensin (5μg/ml) added after the first hour to trap cytokines intracellularly. Surface staining followed by fixation/permeabilization and intracellular staining for IFN-γ provides critical functional data .

• Cytotoxicity assays: Five-hour 51Cr release assays measure the cytolytic capacity of NK cells and cytotoxic T lymphocytes from spleen and lymph node cell suspensions. For CTL activity, five-day restimulation cocultures with irradiated (120 Gy) tumor cells are recommended to expand tumor-specific T cells before assessing killing function .

• Depletion studies: Selective depletion of specific immune cell populations using monoclonal antibodies (anti-CD8, anti-NK1.1, etc.) helps establish their necessity in the therapeutic process. Parallel experiments in gene-targeted mice (e.g., IFN-γ-deficient) can further clarify molecular requirements .

How does anti-CD137 antibody therapy compare with conventional myeloma treatments in preclinical models?

Comparative evaluation of anti-CD137 antibody therapy against established myeloma treatments provides important context for potential clinical translation. In the 5TGM1 disseminated myeloma model, anti-CD137 monotherapy demonstrated clear therapeutic efficacy, though not matching the potency of the proteasome inhibitor bortezomib .

Anti-CD137 treatment significantly reduced skeletal and visceral tumor burden, with only one out of ten mice showing spleen and liver involvement compared to seven or more out of ten in control groups. The therapy also reduced weight loss associated with disease progression and significantly decreased serum monoclonal paraprotein concentration compared to vehicle or control antibody treatments .

What factors influence CD137 expression on immune cells and how might this affect therapeutic outcomes?

CD137 expression on immune cells is dynamically regulated by various stimuli, with important implications for therapeutic targeting. In CD8+ T cells, CD137 expression is induced upon T cell receptor (TCR) engagement and enhanced by costimulatory signals. Experimental protocols using plate-bound anti-CD3 antibody (145.2C11, 1 μg/ml) with or without soluble anti-CD28 (5 μg/ml) demonstrate that CD28 signaling significantly enhances CD137 expression on activated CD8+ T cells .

Despite this relationship, anti-CD137 antibody therapy remains effective in CD28-deficient mice, indicating that sufficient CD137 expression occurs even in the absence of CD28 costimulation. This finding has important implications for patients with compromised costimulatory pathways, suggesting they might still benefit from anti-CD137 therapy .

For NK cells, the pathways leading to CD137 expression are less clearly defined. Research suggests that recognition of tumor cells through activating NK receptors may trigger CD137 upregulation. The increased accumulation of NK cells in tumor-draining lymph nodes following anti-CD137 treatment indicates potential effects on NK cell migration or proliferation, which may contribute to therapeutic efficacy independently of expression levels .

What experimental controls should be included in anti-CD137 antibody studies?

Robust experimental design for anti-CD137 antibody studies requires comprehensive controls to establish specificity and validity of findings. Recommended controls include:

• Isotype-matched control antibodies: Use of rat IgG of the same isotype as the anti-CD137 antibody controls for non-specific effects related to Fc receptor interactions or general immunoglobulin administration. All experimental groups should receive equivalent protein doses on identical schedules .

• Cellular depletion controls: When conducting depletion studies to identify required cell populations, include groups with alternative cell depletions and mock depletion (isotype control antibodies) to demonstrate specificity. Confirm depletion efficiency by flow cytometry of peripheral blood or lymphoid tissues .

• Genetic models: Utilization of gene-targeted mice (e.g., IFN-γ-deficient, CD28-deficient) provides definitive evidence for molecular requirements. Include wild-type littermates as the appropriate genetic background controls .

• Treatment timing variations: Testing delayed treatment initiation helps distinguish preventive from therapeutic effects and establishes the efficacy window for intervention. This is particularly important for translational relevance, as human patients typically present with established disease .

• Pharmacological inhibitors: For mechanistic studies, include groups receiving neutralizing antibodies (e.g., anti-IFN-γ) or small molecule inhibitors of relevant pathways alongside genetic approaches to corroborate findings through complementary methods .

How should researchers monitor for potential adverse effects of anti-CD137 antibody therapy?

Comprehensive monitoring for potential adverse effects of anti-CD137 antibody therapy is essential for accurate interpretation of preclinical results and clinical translation. Researchers should implement the following monitoring protocols:

• Weight tracking: Regular body weight measurements provide a general indicator of animal health. Significant weight loss (>20% of initial body weight) may indicate treatment toxicity rather than disease progression, requiring careful distinction .

• Liver function assessment: Because hepatotoxicity has been reported with some immunostimulatory antibodies, serum analysis of liver enzymes (ALT, AST) should be performed at regular intervals during treatment .

• Cytokine release monitoring: Measurement of serum proinflammatory cytokines (TNF-α, IL-6, IL-1β) after treatment initiation can detect potential cytokine release syndrome, which may limit therapeutic application .

• Histopathological examination: Tissue samples from major organs (liver, lung, kidney, spleen) should undergo histopathological assessment for inflammation, tissue damage, or immune cell infiltration unrelated to tumor involvement .

• Autoimmunity markers: Regular screening for autoantibody development and signs of autoimmune manifestations helps detect potential breaking of self-tolerance with prolonged immune activation .

What combination strategies might enhance anti-CD137 antibody efficacy against multiple myeloma?

Anti-CD137 antibody therapy shows considerable potential for enhancement through rational combinations with other treatment modalities. Promising combination strategies include:

• Conventional anti-myeloma agents: Proteasome inhibitors (bortezomib, carfilzomib) or immunomodulatory drugs (lenalidomide, pomalidomide) may synergize with anti-CD137 by increasing immunogenic cell death and enhancing presentation of tumor antigens to the immune system .

• Checkpoint inhibitors: Combining anti-CD137 with checkpoint blockade (anti-PD-1, anti-CTLA-4) could counteract T cell exhaustion while simultaneously delivering activating signals, potentially overcoming resistance mechanisms .

• Tumor antigen vaccines: Vaccination approaches that increase the frequency of tumor-specific T cells may enhance the effectiveness of subsequent anti-CD137 therapy by providing a larger pool of cells that can be activated and expanded .

• NK cell-enhancing strategies: Given the critical role of NK cells in anti-CD137 efficacy, combinations with IL-15 or anti-KIR antibodies might further potentiate NK cell function and anti-tumor activity .

• Radiation therapy: Local radiation could increase tumor antigen release and enhance immune infiltration of tumors, potentially synergizing with anti-CD137-mediated immune activation in a strategy that targets both local and disseminated disease .

How might anti-CD137 antibody therapy be translated from preclinical models to clinical applications for multiple myeloma?

Translating anti-CD137 antibody therapy from preclinical myeloma models to clinical applications requires addressing several key considerations:

• Patient selection strategies: Given the immune-mediated mechanism of action, patients with evidence of preserved immune function, minimal prior therapy, or measurable residual disease after conventional treatment might benefit most. Biomarker studies correlating baseline immune parameters with response could identify optimal candidates .

• Dosing optimization: Clinical protocols must balance efficacy with safety concerns. Intermittent dosing schedules similar to those effective in preclinical models (e.g., administration on days 4, 8, 14, and 18) may provide optimal immune stimulation while minimizing toxicity risks .

• Response assessment: Beyond conventional myeloma response criteria (paraprotein levels, bone marrow plasma cell percentage), immune monitoring for therapy-induced changes in circulating and bone marrow-infiltrating lymphocytes may provide valuable early indicators of biological activity .

• Managing immune-related adverse events: Protocols for early recognition and management of potential immune-related adverse events, drawing on experience from other immunotherapies, will be essential for safe clinical implementation .

• Rational sequencing with standard therapies: Determining optimal timing of anti-CD137 therapy in relation to conventional treatments (before, after, or concurrent) represents a critical translational question that may significantly impact clinical outcomes .